Navigation Links
Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Date:7/19/2010

ick="var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='98743299';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.aegera.com">www.aegera.com.

About Centre for Clinical Trials of the Chinese University of Hong Kong

The Centre for Clinical Trials (CCT) was established under the School of Public Health of the Chinese University of Hong Kong in order to promote good clinical practice in clinical research and clinical trials in Asia. It provides quality education, clinical research services and infrastructure to support local, regional and international clinical trials. For more information about CCT, please visit www.cct.cuhk.edu.hk


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
3. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
4. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
5. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... CAMPBELL, Calif. , Sept. 23, 2014  Age ... Rick Noodleman , has become one of the ... the world,s only "picoseconds" aesthetic laser for tattoo removal. ... treatments and better results. "For years, tattoo removal has ... treatment," says Dr. Noodleman. "This is an opportunity to ...
(Date:9/23/2014)... Mass. , Sept. 23, 2014   GenoSpace ... a comprehensive suite of tools to enable the broad ... today announced that it has been awarded Phase I ... (SBIR) from the National Institutes of Health (NIH) to ... Logo - http://photos.prnewswire.com/prnh/20140922/147649 ...
(Date:9/23/2014)... 23, 2014 Healthcare professionals, ... will convene at the Society for Integrative ... held October 26-28 in Houston, Texas to ... practice in individualized integrative cancer care. This ... psychologists, nutritionists, naturopaths, acupuncturists, and other complementary ...
(Date:9/22/2014)... CLARA, Calif. , Sept. 22, 2014 ... leading source of health information, today released the findings ... novel insights regarding physician and patient perspectives on health ... Eric Topol , a leading authority in the fields ... Editor-in-Chief of Medscape and Chief Academic Officer of Scripps ...
Breaking Biology Technology:Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4
... 6, 2012 Arteriocyte, a leading biotechnology company ... announced today approval from the Food and Drug ... trial using its Magellan MAR01™ technology in the ... Exemption (IDE 15013) allows Arteriocyte and its clinical ...
... clusters of pancreatic beta-cells that live much longer and secrete ... valuable new tools for studying pancreatic diseases such as diabetes ... in an article in Tissue Engineering, Part C, Methods ... . The article is available free online at the ...
... dose of carbon nanotubes more than doubles the growth ... production of everything from lifesaving medications to sweeteners to ... the first to show that carbon nanotubes boost plant ... ACS Nano . Mariya V. Khodakovskaya and colleagues ...
Cached Biology Technology:Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 3
(Date:9/23/2014)... gotten a lot greener thanks to a novel technique ... uses solar energy to accelerate tailings pond reclamation efforts ... a light source to treat oil sands process affected ... El-Din and James Bolton have found that using the ... just as efficiently but at a much lower cost. ...
(Date:9/23/2014)... will award funds to support the next phase of ... ways of predicting drug safety and effectiveness. Researchers will ... tissue chips and combine them into an integrated system ... body. Led by the National Center for Advancing Translational ... $17 million in 2014 with additional support over the ...
(Date:9/23/2014)... Eureka Therapeutics, Inc. announced today that the Company has ... new funding will be used to expand the Company,s ... clinical development. New investor Yuan Capital led the round, ... including Acorn Campus Ventures, Suma Venture and Harbinger Venture ... and development of fully-human antibodies engineered to mimic the ...
Breaking Biology News(10 mins):Solar energy-driven process could revolutionize oil sands tailings reclamation 2NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4
... data wirelessly for more than a year in early stage ... Institutes of Health. In addition to allowing for more natural ... represents a potential major step toward cord-free control of advanced ... is in the April 2013 issue of the Journal ...
... the University of Massachusetts Amherst led by microbiologist Derek ... sulfurreducens conducts electricity very effectively along metallic-like "microbial ... of such a novel biological electron transfer mechanism, but ... behavior represents a paradigm shift. It goes against all ...
... of adoption has taxed the minds of evolutionary scientists since ... According to Richard Dawkins,s description, adoption is "a double ... to increase, your own reproductive success, but you improve someone ... take care of young that are not related to them? ...
Cached Biology News:Wireless, implanted sensor broadens range of brain research 2Wireless, implanted sensor broadens range of brain research 3UMass Amherst researchers reveal mechanism of novel biological electron transfer 2UMass Amherst researchers reveal mechanism of novel biological electron transfer 3Risk management in fish: How cichlids prevent their young from being eaten 2
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: